Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity
Tevogen Bio (NASDAQ: TVGN) has received recognition from Yale University for CEO Dr. Ryan Saadi's vision of making healthcare more affordable and accessible. The company specializes in developing off-the-shelf, genetically unmodified CD8+ T cell therapies with reduced manufacturing complexity and costs.
Tevogen's business model stands out for its capital-efficient structure, having reached its current stage with significantly lower spending compared to industry standards over five years. The company maintains full ownership of its core intellectual property and operates with a lean monthly cash run rate, avoiding costly licensing overhead.
Tevogen Bio (NASDAQ: TVGN) è stata riconosciuta dalla Yale University per la visione del suo CEO, il Dr. Ryan Saadi, volta a rendere l'assistenza sanitaria più accessibile e conveniente. L'azienda si dedica allo sviluppo di terapie CD8+ con cellule T pronte all'uso e geneticamente non modificate, con processi produttivi meno complessi e costosi.
Il modello di business di Tevogen si distingue per la sua struttura capital-efficient: in cinque anni ha raggiunto la fase attuale con investimenti molto inferiori rispetto agli standard del settore. L'azienda detiene la piena proprietà della proprietà intellettuale chiave e opera con un basso burn rate mensile, evitando i costi elevati legati a licenze esterne.
Tevogen Bio (NASDAQ: TVGN) ha recibido reconocimiento de la Universidad de Yale por la visión de su CEO, el Dr. Ryan Saadi, de hacer la atención sanitaria más asequible y accesible. La compañía se especializa en desarrollar terapias con células T CD8+ listas para usar y genéticamente no modificadas, con una manufactura menos compleja y costosa.
El modelo de negocio de Tevogen destaca por su estructura de capital eficiente: en cinco años ha llegado a su etapa actual gastando considerablemente menos que los estándares de la industria. La empresa mantiene la propiedad total de su propiedad intelectual central y opera con un reducido ritmo de gasto mensual, evitando los elevados gastos por licencias.
Tevogen Bio (NASDAQ: TVGN)는 CEO인 Dr. Ryan Saadi의 의료 서비스를 더 저렴하고 접근 가능하게 만들겠다는 비전으로 예일대학교의 인정을 받았습니다. 이 회사는 제조 복잡성과 비용을 낮춘 즉시 사용 가능한 유전적으로 비변형 CD8+ T세포 치료제 개발을 전문으로 합니다.
Tevogen의 비즈니스 모델은 자본 효율성이 높은 구조로 돋보입니다. 5년 동안 업계 표준보다 훨씬 적은 지출로 현재 단계에 도달했으며, 핵심 지적 재산권을 전적으로 보유하고 월별 현금 소진률을 낮게 유지하여 비싼 라이선스 비용을 피하고 있습니다.
Tevogen Bio (NASDAQ: TVGN) a reçu une reconnaissance de l'université de Yale pour la vision de son CEO, le Dr Ryan Saadi, visant à rendre les soins de santé plus abordables et accessibles. L'entreprise se spécialise dans le développement de thérapies cellulaires CD8+ prêtes à l'emploi et génétiquement non modifiées, avec une complexité et des coûts de fabrication réduits.
Le modèle économique de Tevogen se distingue par sa structure économe en capital : en cinq ans, elle a atteint son stade actuel avec des dépenses bien inférieures aux normes du secteur. L'entreprise conserve la pleine propriété de sa propriété intellectuelle essentielle et fonctionne avec un faible burn rate mensuel, évitant les coûts élevés liés aux licences.
Tevogen Bio (NASDAQ: TVGN) wurde von der Yale University für die Vision seines CEO Dr. Ryan Saadi anerkannt, die Gesundheitsversorgung erschwinglicher und zugänglicher zu machen. Das Unternehmen spezialisiert sich auf die Entwicklung von sofort einsatzbereiten, genetisch unveränderten CD8+-T-Zelltherapien mit geringerer Herstellungs-komplexität und -kosten.
Das Geschäftsmodell von Tevogen zeichnet sich durch eine kapital-effiziente Struktur aus: In fünf Jahren hat es den aktuellen Meilenstein mit deutlich geringeren Ausgaben als branchenüblich erreicht. Das Unternehmen besitzt die zentralen geistigen Eigentumsrechte vollständig und arbeitet mit einer schlanken monatlichen Cash-Burn-Rate, wodurch teure Lizenzkosten vermieden werden.
- Achieved development milestones with significantly lower capital expenditure than industry norm
- Maintains full ownership of core intellectual property, avoiding licensing costs
- Operates with lean monthly cash run rate and preserved equity
- Developed innovative manufacturing process for reduced complexity and costs
- Will require additional capital raising to execute business plan
- Limited operating history as noted in risk factors
- Faces significant competition and rapid technological changes in the market
WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its appreciation to Yale University for recognizing Founder and CEO Dr. Ryan Saadi, MPH ’95, and the Company’s mission of health equity.
In recognition from Yale School of Public Health leadership, Dr. Saadi was commended for his “vision to make healthcare more affordable and accessible” and the impact that Tevogen Bio has had on the world.
Tevogen’s business model is designed to withstand current market pressures through a lean, capital-efficient structure. By fully owning its core intellectual property and avoiding costly licensing overhead, the Company is uniquely positioned to develop off-the-shelf, genetically unmodified CD8+ T cell therapies that aim to reduce manufacturing complexity and cost.
“We are humbled and honored by this recognition,” said Dr. Saadi. “As Yale has highlighted, affordability and accessibility are not just aspirational goals for Tevogen, they are the foundation of how we operate. We’ve deliberately avoided the billion-dollar burn norm of our industry, reaching this stage well under typical industry spend in five years with equity largely preserved and a lean monthly cash run rate. We believe that true innovation not only delivers better patient outcomes but also achieves commercial success at lower cost. With access to capital and a strong operational platform, we remain steadfast in our mission to make transformative therapies broadly available.”
Forward-Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/22c7a860-fe4c-4db5-a33a-8208510f0445
FAQ
What is Tevogen Bio's (TVGN) approach to making cell therapies more accessible?
How has Tevogen Bio's business model differed from typical biotech companies?
Who is Dr. Ryan Saadi and why was he recognized by Yale University?
What are the main challenges facing Tevogen Bio (TVGN)?
What types of treatments is Tevogen Bio developing?
